即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS号 | 266359-93-7 | 货号 | BCP30625 |
中文名 | Repertaxin L-赖氨酸盐 | ||
英文名 | Repertaxin L-lysine salt | ||
中文别名 | |||
英文别名 | Reparixin L-lysine;Repertaxin L-lysine salt;(2S)-2,6-diaminohexanoic acid;(2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide; | ||
SMILES | CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C.C(CCN)CC(C(=O)O)N | ||
化学名称 | |||
分子式 | C14H21NO3S.C6H14N2O2 | 分子量 | 429.58 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | The efficacy of RPX (tested in a wide range of concentrations (1-1000 nM)) was lower in cells expressing Ile43Val CXCR1 mutant (IC50 values of 0.0056 and 0.08 uM for CXCR1 weight and CXCR1 Ile43Val, respectively). Treatment with reparixin significantly counteracts secondary degeneration by reducing oligodendrocyte apoptosis, migration to the injury site of neutrophils and ED-1-positive cells. The best beneficial outcome of reparixin treatment required 7-day administration either by i.p. route (15 mg/kg) or subcutaneous infusion via osmotic pumps (10 mg/kg), reaching a steady blood level of 8 microg/ml. Reparixin effectively decreased systolic blood pressure and increased the blood flow. The thoracic aorta wall thickness was significantly decreased in SHR-R compared to SHR-N. Pre-treatment with reparixin reduced the motor deficits observed in this model of ischemia and reperfusion. Myeloperoxidase activity and IL-iβ were reduced in the reparixin-treated group. Histological analysis revealed that ischemic injury was also attenuated by reparixin pre-treatment. |
Tags:Repertaxin L-lysine salt 供应商,Repertaxin L-lysine salt 购买,Repertaxin L-lysine salt 生产,Repertaxin L-lysine salt 批量,Repertaxin L-lysine salt 供应,Repertaxin L-lysine salt 订购,Repertaxin L-lysine salt 采购